Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

901 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Challenges and advances in clinical applications of mesenchymal stromal cells (2021, background): “The adverse immune reactions induced by viral transduction were reported to impair the stability of transgenes [126, 127].”
Gene therapy comes of age (2018, positive): “Problems that still need to be addressed include the delayed CD8 T cell response to the capsid, which has been well controlled with a short course of steroids with some AAV vectors but not with others, and the prevalence—particularly in the adult population— of preexisting neutralizing antibodies to”
Current Strategies for Brain Drug Delivery (2018, background): “So far, AVV vectors have demonstrated exceptional safety profiles in humans as well as the ability for gene delivery in the brain, although a concern on immunogenicity still remains [21].”